Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03319459
Title FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics

hepatocellular carcinoma

Her2-receptor positive breast cancer

head and neck squamous cell carcinoma

renal cell carcinoma

stomach cancer

colorectal cancer

Advanced Solid Tumor



FATE-NK100 + Trastuzumab

Cetuximab + FATE-NK100

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UCSD Moores Cancer Center San Diego California 92037 United States Details
University of Minnesota Minneapolis Minnesota 55455 United States Details
The Ohio State University James Cancer Hospital Columbus Ohio 43210 United States Details
Baylor Scott & White Research Institute Dallas Texas 75246 United States Details
*Shaded cells indicate that there was no data available from for the field